Wall Street Zen cut shares of Cue Biopharma (NASDAQ:CUE – Free Report) from a hold rating to a sell rating in a research report sent to investors on Sunday morning.
Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Cue Biopharma in a report on Thursday, August 13th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.
Read Our Latest Report on Cue Biopharma
Cue Biopharma Stock Performance
Cue Biopharma (NASDAQ:CUE – Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($24.14) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($22.45). The firm had revenue of $7.88 million for the quarter, compared to analyst estimates of $3.00 million. Cue Biopharma had a negative net margin of 435.83% and a negative return on equity of 620.06%.
Insider Buying and Selling
In other Cue Biopharma news, insider Sumita Ray sold 8,829 shares of Cue Biopharma stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $30.09, for a total transaction of $265,664.61. Following the transaction, the insider directly owned 118,545 shares of the company’s stock, valued at approximately $3,567,019.05. The trade was a 6.93% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Shao-Lee Lin sold 40,000 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $27.10, for a total value of $1,084,000.00. Following the completion of the sale, the chief executive officer owned 724,253 shares in the company, valued at $19,627,256.30. This trade represents a 5.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 72,715 shares of company stock valued at $2,041,555 in the last three months. Insiders own 14.56% of the company’s stock.
Institutional Trading of Cue Biopharma
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. bought a new position in shares of Cue Biopharma in the 2nd quarter worth about $83,000. Bank of America Corp DE acquired a new position in shares of Cue Biopharma in the 2nd quarter valued at about $219,000. Seven Fleet Capital Management LP bought a new stake in shares of Cue Biopharma during the 2nd quarter valued at about $338,000. Persistent Asset Partners Ltd bought a new stake in shares of Cue Biopharma during the 2nd quarter valued at about $389,000. Finally, Texas Capital Bank Wealth Management Services Inc acquired a new stake in Cue Biopharma during the second quarter worth approximately $722,000. Institutional investors and hedge funds own 35.04% of the company’s stock.
About Cue Biopharma
Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.
Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.
Featured Stories
- Five stocks we like better than Cue Biopharma
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
